Bio
Girish Nadkarni, MD, MPH, is an Assistant Professor in the Division of Nephrology, as well as Clinical Director of the Charles Bronfman Institute for Personalized Medicine. As an expert physician-scientist, Dr. Nadkarni bridges the gap between clinical care and innovative research. Dr. Nadkarni earned his Bachelor of Medicine and Surgery degrees from Topiwala National Medical College in Mumbai, India, and a Master of Public Health degree from Johns Hopkins Bloomberg School of Public Health. He completed his internship and residency at Mount Sinai Morningside, formerly Mount Sinai St. Luke’s, and joined the Division of Nephrology within the Icahn School of Medicine at Mount Sinai as a fellow in 2012.
From his earliest days of residency in nephrology through present day, Dr. Nadkarni has continuously provided comprehensive renal care to patients both at Mount Sinai and at the James J. Peters Veterans Medical Center in the Bronx, New York. His expert patient care includes weaving cutting-edge research into his inpatient consultations and outpatient nephrology visits, ensuring that patients receive the most comprehensive care. He also serves as a mentor to fellows and residents rotating on nephrology services.
Research Focus
As an active clinician and investigator, a commitment to improved health and patient outcomes is a guiding principle of Dr. Nadkarni’s activity. He believes that the most effective treatment utilizes the newest technologies and computing systems in the world. To that end, Dr. Nadkarni’s research career has focused on three major areas: utilizing electronic medical record data for genotype-phenotype association studies, utilizing electronic medical record and biospecimens collected during routine clinical care for the development and validation of novel biomarkers of progression of chronic kidney disease, and utilizing big data approaches for better stratification, understanding, and prediction of chronic kidney disease progression. Dr. Nadkarni is currently leading the Digital Health Cohort at Mount Sinai, which leverages the expert data analysis, digital engineering, and electronic capabilities of HPI•MS, and enables rapid translation between research and clinical care.
Along with his work at HPI•MS, Dr. Nadkarni also leads a groundbreaking collaboration with RenalytixAI, a newly launched artificial intelligence technology company catalyzed by Mount Sinai’s BioMe™ biobank, with the goal of creating a model that will monitor and flag patients at risk for kidney disease. The AI system can process large volumes of data from disparate data sources—including BioMe™ , the Mount Sinai Data Warehouse, and clinical data—and create a powerful model to predict kidney disease. AI-enabled diagnostics have the potential to introduce a new level of personalized medicine by providing precise diagnostic information for specific patient populations. RenalytixAI aims to predict how kidney disease may progress, a patient’s response to a specific drug therapy, and strategies for clinical management of the disease. The new tool will have the potential to transform how we detect, monitor, and treat a devastating disease that impacts many millions of patients around the world. In October 2019, RenalytixAI was recognized by Mount Sinai as Deal of the Year, celebrating its research breakthroughs and strong commercial partnership for advancement.